
---
title: Molecular Cell _ Volume 81, Issue 6 (Mar 18, 2021)
categories: 
    - 科学期刊
    - Cell - 封面故事
author: Cell - 封面故事
comments: false
date: Thu, 18 Mar 2021 00:00:00 GMT
thumbnail: https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/atypon:cms:attachment:img:d27e6:rev:1615868130203-1670:pii:S1097276520X00074/cover.tif.jpg
---

<div>   
<div align="center"><img src="https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/atypon:cms:attachment:img:d27e6:rev:1615868130203-1670:pii:S1097276520X00074/cover.tif.jpg" alt="On the cover: In this issue of <em>Molecular Cell,</em> Heider et al. (1170–1186) investigate the molecular function of immunomodulatory
drugs (IMiDs) in multiple myeloma and describe their target, CRBN, as a transmembrane
protein-specific co-chaperone of the HSP90-AHA1 axis. Visually, CRBN-orchestrated
HSP90 knitting of a LAT1 transmembrane protein is inhibited by the IMiD thalidomide.
The illustration shows the vivid complexity of protein folding that is leveraged for
the anti-tumor efficacy of IMiDs by targeting CRBN. Image by Dr. Johannes Richers
(<a href=" https: jorichers.com" target="_blank" referrerpolicy="no-referrer">https://jorichers.com)."></div>  
</div>
            